What Is Compounded Tirzepatide? What Compounding Means, How It Differs From Zepbound, and What to Check

"Compounded tirzepatide" is one of the most-searched drug phrases in the country, and one of the least-defined. Telehealth companies use it as a product name. Critics use it as a synonym for counterfeit. Neither is right, and the gap between them is where most of the bad buying decisions get made.

Compounding is a real, legal, narrowly-defined activity with a section of federal law all to itself. Understanding what that section actually says is the fastest way to tell a legitimate compounded product from a company using the word as a marketing veneer — and it takes about four minutes.

What compounding actually is, read off the statute

Section 503A of the Federal Food, Drug, and Cosmetic Act — 21 U.S.C. §353a — does something specific: it says three other parts of the drug law do not apply to a compounded product. Those three are §351(a)(2)(B) (the requirement to be made under current good manufacturing practice), §352(f)(1) (the requirement to bear adequate directions for use), and §355 (the requirement to be an FDA-approved new drug)¹.

That is the whole trick. A compounded drug is not approved by FDA because the statute exempts it from needing to be. In exchange, the exemption comes with conditions, and they are tight. The drug must be "compounded for an identified individual patient based on the receipt of a valid prescription order," by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician¹. The bulk drug substance used must comply with a United States Pharmacopeia or National Formulary monograph if one exists — or, failing that, be "a component of drugs approved by the Secretary" — must come from an FDA-registered establishment, and must arrive "accompanied by valid certificates of analysis for each bulk drug substance¹."

Tirzepatide clears that last hurdle by an obvious route: it is the active ingredient in two FDA-approved products, Mounjaro and Zepbound, so it qualifies as a component of an approved drug. That is why compounded tirzepatide is legally possible at all in a way that, say, compounded retatrutide is not.

Then comes the condition that governs this entire market. A compounder may not "compound regularly or in inordinate amounts … any drug products that are essentially copies of a commercially available drug product¹." The statute's own definition carves out one exception, and it is worth reading exactly: a product is not essentially a copy if there is "a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the comparable commercially available drug product¹."

Read that clause slowly. The exception is patient-specific, prescriber-determined, and must produce a significant difference for that person. "It costs less" is not a change. It is a price.

Why a compounded tirzepatide exists at all

Compounding exists for the patient the approved product cannot serve. FDA's own explanation gives the textbook cases: a patient allergic to a dye in the commercial product, or an elderly patient or child who cannot swallow a tablet and needs a liquid². Nobody built a national industry on those.

The industry was built on the statute's other lane — the one that opens when the brand-name drug is on FDA's shortage list. Tirzepatide had been in shortage since 2022, and while it was, both 503A pharmacies and 503B outsourcing facilities had room to fill the gap without the "essentially a copy" bar closing on them. That lane has since shut: FDA determined the shortage resolved, re-determined it after a court remand, and enforcement discretion ended for 503A pharmacies in early 2025 and for 503B facilities weeks later⁵⁶. Our dated walk-through of that timeline covers every step with FDA's own dates, and it matters commercially: a company still selling compounded tirzepatide at subscription scale today is not operating in the shortage lane it was built for. It is operating on the patient-specific exception above, or on FDA's small-scale allowance, or on neither.

How a compounded vial actually differs from Zepbound

This is where most explainers stop at "it's not FDA-approved" and skip the concrete differences that change what shows up at your door.

It is not a generic, and the distinction is not semantic. FDA states it directly: a generic drug is approved under section 505(j) and must establish therapeutic equivalence to the brand, "while a compounded drug is not approved by FDA²." No compounded tirzepatide has been through a trial demonstrating it performs like Zepbound. The trials you have read about were run on Lilly's finished product, at Lilly's concentrations, made under Lilly's manufacturing controls. Those results describe that product. They do not transfer to a different vial by virtue of sharing a molecule name.

The oversight is genuinely different depending on which kind of pharmacy made it. Drugs compounded in a 503B outsourcing facility are subject to current good manufacturing practice requirements; drugs compounded by a licensed pharmacist in a state-licensed 503A pharmacy are not². And the inspector differs too — state boards of pharmacy have primary day-to-day responsibility for 503A pharmacies, while FDA primarily oversees and inspects registered outsourcing facilities on a risk-based schedule². This is the single most substantive fact behind a provider's "503A" or "503B" claim, and it is why a company that will not say which one applies has told you less than it appears to have.

The dose form is different in a way that matters at the syringe. Zepbound ships in six single-dose pen or vial strengths — 2.5, 5, 7.5, 10, 12.5 and 15 mg, each in 0.5 mL — plus multi-dose vials and pens holding four doses each, at six matched concentrations from 4.17 mg/mL up to 25 mg/mL⁷. Notice what Lilly did there: as the dose rises, the concentration rises with it, so the injected volume stays fixed at 0.6 mL. A compounded vial has one concentration, and the volume you draw changes with every step of the ladder. That is not a defect — it is just a different product architecture, and it is the reason dosing a compounded vial requires arithmetic that dosing a pen does not. Our walk through tirzepatide's label ladder covers how that mapping actually works, and our reconstitution calculator and units-to-mg converter do the arithmetic on a number a prescriber gave you.

FDA has reported real harm from exactly this gap: it has received multiple adverse-event reports, "some requiring hospitalization," related to dosing errors with compounded injectable semaglutide products, "from patients measuring and self-administering incorrect doses of the drug, and in some cases, health care professionals miscalculating doses⁴."

What to actually check before you buy

FDA publishes its own list of telehealth warning signs, and it is unusually blunt for an agency document. It says to look out for a company that "makes claims such as the compounded drug is the same as an FDA-approved drug," that "offers medicine at deep discounts or prices that seem too good to be true," that "does not require a screening and prescription by a licensed doctor before providing medicine," that has no licensed doctor available afterwards, or that "includes a pharmacy name on the label that you think might be fraudulent⁴."

That last one is not hypothetical. FDA states it is "aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label. In some cases, the compounding pharmacies identified on the labels of the products do not exist. In other cases, the labels … contain the name of a licensed pharmacy that, based on information FDA has gathered, did not compound these products⁴."

Which turns the abstract advice into three concrete, checkable things:

• •A named pharmacy. Not "our network of licensed compounding pharmacies." A name. If a provider names one, you can look it up; if it names none, there is nothing to verify and nothing to compare against the label when the box arrives.
• •A stated regulatory category. 503A or 503B, stated by the company in writing. As above, these are materially different regimes with different inspectors and different manufacturing rules. A site that hedges between them — several do, sometimes in adjacent sentences — has not answered the question. Registered outsourcing facilities are published by FDA in a public list you can search yourself⁸.
• •A price you will actually be charged. This is the one FDA cannot police and where the most reader money leaks. A large share of the headline prices in this category are prepay tiers, first-month teasers, or figures that exclude a required membership. Our tirzepatide provider comparison reads each company's own pages for the standing month-to-month number, and our cost view of the same roster sorts it by that number rather than by editorial rank.

The honest summary

Compounded tirzepatide is a real category of medicine, made under a real statutory exemption, that is not FDA-approved, not a generic, not independently trial-tested as a finished product, and not overseen the same way depending on which kind of pharmacy made it. None of that makes it illegitimate. It makes it a product whose quality depends almost entirely on who made it — which is precisely the fact the cheapest marketing in this category works hardest to obscure.

FDA's own framing is the right one to end on: compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug," and "unnecessary use of compounded drugs may expose patients to potentially serious health risks²" — with the agency noting separately that poor compounding practice can produce "a drug that contains too much or too little active ingredient³." If you are buying anyway, the questions above are the ones that separate the companies that can answer them from the ones that would rather you did not ask. The same questions apply, with one important addition, to compounded semaglutide — where FDA has flagged a salt-form problem that has no tirzepatide equivalent.